Citius Pharmaceuticals (CTXR) News Today → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free CTXR Stock Alerts $0.69 -0.01 (-0.91%) (As of 05/10/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCitius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferencesprnewswire.com - May 10 at 8:30 AMCitius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 3.1%marketbeat.com - May 9 at 12:21 AMCitius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offeringprnewswire.com - April 30 at 4:05 PMCitius Pharmaceuticals Announces $15 Million Registered Direct Offeringprnewswire.com - April 26 at 8:00 AMCTXR Citius Pharmaceuticals, Inc.seekingalpha.com - April 14 at 10:43 AMCitius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphomaprnewswire.com - April 11 at 8:30 AMCitius Pharmaceuticals (NASDAQ:CTXR) Trading Down 3.8%marketbeat.com - April 9 at 12:47 AMCitius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conferenceprnewswire.com - April 4 at 8:30 AMCTXR Apr 2024 7.500 putfinance.yahoo.com - March 20 at 9:52 AMCTXR May 2024 2.500 callfinance.yahoo.com - March 20 at 9:52 AMCitius Pharmaceuticals Incedition.cnn.com - March 20 at 9:52 AMCitius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatmentmsn.com - March 18 at 12:48 PMCitius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick Factsmarkets.businessinsider.com - March 18 at 12:48 PMCitius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphomafinance.yahoo.com - March 18 at 12:48 PMCitius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Programprnewswire.com - March 7 at 8:30 AMCitius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Programprnewswire.com - March 7 at 8:30 AMCitius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registrationfinance.yahoo.com - February 26 at 12:16 PMCitius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registrationprnewswire.com - February 26 at 7:30 AMCitius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferencesfinance.yahoo.com - February 23 at 11:36 AMCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Updateprnewswire.com - February 14 at 4:30 PMBuy Rating for Citius Pharmaceuticals Backed by Resubmission of Lymphir BLA and Potential Orphan Drug Exclusivitymarkets.businessinsider.com - February 14 at 4:15 PMCitius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphomafinance.yahoo.com - February 14 at 8:50 AMCitius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphomaprnewswire.com - February 14 at 8:01 AMCitius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directorsfinance.yahoo.com - January 23 at 9:41 AMFY2024 Earnings Estimate for Citius Pharmaceuticals, Inc. Issued By HC Wainwright (NASDAQ:CTXR)marketbeat.com - January 18 at 7:47 AMCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Updatemarketbeat.com - January 15 at 11:48 AMStrong Buy Rating for Citius Pharmaceuticals Amid Promising Mino-Lok Progress and Strategic Oncology Spinoutmarkets.businessinsider.com - January 4 at 10:36 AMCitius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Cathetersfinanznachrichten.de - January 2 at 3:15 PMCitius Ekes out Gains as Trials Endbaystreet.ca - January 2 at 10:15 AMCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Updatefinance.yahoo.com - January 2 at 10:15 AMCitius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Cathetersfinance.yahoo.com - January 2 at 10:15 AMCitius Pharmaceuticals (CTXR) Scheduled to Post Earnings on Wednesdaymarketbeat.com - December 19 at 7:22 AMWe Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefullyfinance.yahoo.com - December 3 at 2:28 PMCitius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023finance.yahoo.com - November 9 at 12:42 PMCitius Pharmaceuticals Inc CTXRmorningstar.com - November 8 at 9:43 AMCitius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitorfinance.yahoo.com - October 31 at 9:56 AMTenX To Acquire Citius Pharma's Oncology Subsidiary Via Merger - Quick Factsmarkets.businessinsider.com - October 26 at 10:03 AMCitius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.finance.yahoo.com - October 24 at 10:16 AMCitius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023finance.yahoo.com - September 18 at 5:58 PMCitius Pharmaceuticals Mourns the Loss of Board Member, Howard Safirfinance.yahoo.com - September 13 at 6:23 PMCitius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™finance.yahoo.com - September 8 at 9:57 AMCitius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023finance.yahoo.com - September 6 at 8:48 PMBreakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)finance.yahoo.com - September 4 at 9:54 AMCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - August 14 at 7:11 PMCitius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trialfinance.yahoo.com - August 10 at 9:32 AMHC Wainwright & Co. Maintains Citius Pharmaceuticals (CTXR) Buy Recommendationmsn.com - August 2 at 7:33 AMCitius Pharmaceuticals (CTXR) Gets a Buy from H.C. Wainwrightmarkets.businessinsider.com - August 1 at 9:30 PMWhy Citius Pharmaceuticals Stock Is Plunging Today?msn.com - July 31 at 1:01 PMCitius Shares Fall Premarket After FDA Rejects Cancer Treatment >CTXRmarketwatch.com - July 31 at 8:01 AMCitius Pharma: FDA Issues CRL For LYMPHIRTM BLA For Patients With Cutaneous T-cell Lymphomamarkets.businessinsider.com - July 30 at 4:50 PM Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address The Department of Defense Has a New Drone Contractor (Ad)The Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes. Click here to see how to invest CTXR Media Mentions By Week CTXR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTXR News Sentiment▼0.930.58▲Average Medical News Sentiment CTXR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTXR Articles This Week▼41▲CTXR Articles Average Week Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALLK News Today CUE News Today PMVP News Today ASRT News Today GNLX News Today RLMD News Today RZLT News Today SCTL News Today IOBT News Today OPTN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTXR) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
